<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03908840</url>
  </required_header>
  <id_info>
    <org_study_id>TBI 302-001</org_study_id>
    <nct_id>NCT03908840</nct_id>
  </id_info>
  <brief_title>Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>An Open-label, Multicenter, Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Non-resectable, Non-transplantable, Non-radiofrequency Ablation (RFA) Treatable Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapure Biopharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therapure Biopharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. TBI 302 is being&#xD;
      developed for the treatment of inoperable HCC by intravenous infusion. The objective is to&#xD;
      determine the safety and tolerability of TBI 3002.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and MTD of TBI&#xD;
      302 in patients with non-resectable, non-transplantable HCC. Tumor response will be assessed&#xD;
      at Week 9 (5 weeks following cessation of treatment) according to RECIST (ver 1.1) and AASLD&#xD;
      criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and tolerability) observed during the trial</measure>
    <time_frame>through study completion, up to one year</time_frame>
    <description>The number of TEAEs observed during the trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of Maximum Tolerated Dose</measure>
    <time_frame>through study completion, up to one year</time_frame>
    <description>Determination of Maximum Tolerated Dose of TBI 302</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TBI 302 Safety, Tolerability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Cohorts, Dose escalation TBI 302 will be formulated in 0.9% saline. TBI 302 in a syringe will be administered over approximately 1 hour under constant observation once per week for 4 weeks (on Days 1, 8, 15 and 22).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TBI 302</intervention_name>
    <description>TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)</description>
    <arm_group_label>TBI 302 Safety, Tolerability</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients histologically or cytologically confirmed, unresectable, or metastatic HCC&#xD;
&#xD;
          -  Child-Pugh Category A or B (score 6-7); stable, well-compensated, mild cirrhosis with&#xD;
             minimal or no ascites&#xD;
&#xD;
          -  Male or female patients 18 years of age or older&#xD;
&#xD;
          -  Patients must be willing and able to read, understand and sign a written informed&#xD;
             consent form&#xD;
&#xD;
          -  Male, or female of childbearing potential, must agree to use double barrier&#xD;
             contraception, oral contraceptives or other ways to avoid pregnancy during the study&#xD;
             and for 90 days after the last day of treatment&#xD;
&#xD;
          -  Life expectancy of greater than 3 months&#xD;
&#xD;
          -  Plasma haptoglobin â‰¥ LLN (lower limit of normal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients confirmed with hemolysis confirmed by serum lactate dehydrogenase, serum&#xD;
             haptoglobin or indirect bilirubin levels&#xD;
&#xD;
          -  Patients who have received a blood transfusion within 4 weeks of enrolment&#xD;
&#xD;
          -  Patients with infiltrating diffuse hepatocellular carcinoma, Type 1 or 2 diabetes&#xD;
             mellitus, Hepatitis B or Hepatitis C infection&#xD;
&#xD;
          -  Systemic chemotherapy-naive patients&#xD;
&#xD;
          -  Patients with significant cardiovascular impairment, including history of congestive&#xD;
             heart failure, unstable angina, myocardial infarction, or serious cardiac arrhythmia&#xD;
             within the last 6 months&#xD;
&#xD;
          -  Patient with a history of tumor rupture&#xD;
&#xD;
          -  Patients with serious non-healing wound , ulcer or bone fracture&#xD;
&#xD;
          -  Known positive human immunodeficiency virus (HIV) test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46077</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bert O'Neil, MD</last_name>
      <phone>919-593-2664</phone>
      <email>bhoneil@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Bert O'Neil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Liver</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

